Fernanda Genre

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8910190/publications.pdf

Version: 2024-02-01

59	861	567144 15	552653 26
papers	citations	h-index	g-index

60	60	60	1448
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. Autoimmunity Reviews, 2016, 15, 1013-1030.	2.5	107
2	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. Arthritis and Rheumatology, 2021, 73, 1073-1085.	2.9	81
3	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. Scientific Reports, 2017, 7, 5088.	1.6	44
4	Brief Report: Association of HLAâ€“DRB1*01 With IgA Vasculitis (Henochâ€šSchÃ¶nlein). Arthritis and Rheumatology, 2015, 67, 823-827.	2.9	35
5	Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis. Scientific Reports, 2016, 6, 29713.	1.6	34
6	Adipokines, Biomarkers of Endothelial Activation, and Metabolic Syndrome in Patients with Ankylosing Spondylitis. BioMed Research International, 2014, 2014, 1-11.	0.9	33
7	Association of HLA-B*41:02 with Henoch-SchÃ¶nlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. Arthritis Research and Therapy, 2015, 17, 102.	1.6	33
8	Independent Relationship of Osteoprotegerin Concentrations with Endothelial Activation and Carotid Atherosclerosis in Patients with Severe Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 429-436.	1.0	32
9	The ZC3HC1 rs11556924 polymorphism is associated with increased carotid intima-media thickness in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2013, 15, R152.	1.6	26
10	Osteoprotegerin Concentrations Relate Independently to Established Cardiovascular Disease in Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 39-45.	1.0	26
11	Anti-TNF-Î± therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients. Rheumatology International, 2015, 35, 2069-2078.	1.5	25
12	Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 465-473.	0.4	19
13	Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2013, 31, 761-6.	0.4	18
14	Endothelial Progenitor Cells as a Potential Biomarker in Interstitial Lung Disease Associated with Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 4098.	1.0	16
15	Cardiovascular risk stratification in axial spondyloarthritis: carotid ultrasound is more sensitive than coronary artery calcification score to detect high-cardiovascular risk axial spondyloarthritis patients. Clinical and Experimental Rheumatology, 2018, 36, 73-80.	0.4	16
16	Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-Î± antagonist therapy. Clinical and Experimental Rheumatology, 2013, 31, 538-45.	0.4	15
17	Antitumour necrosis factor Î± treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients. Annals of the Rheumatic Diseases, 2014, 73, 941-943.	0.5	14
18	Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis. Scientific Reports, 2017, 7, 10525.	1.6	14

#	Article	IF	Citations
19	Omentin: a biomarker of cardiovascular risk in individuals with axial spondyloarthritis. Scientific Reports, 2020, 10, 9636.	1.6	13
20	Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-Î± antagonist therapy. Clinical and Experimental Rheumatology, 2013, 31, 365-71.	0.4	13
21	SMAD3 rs17228212 Gene Polymorphism Is Associated with Reduced Risk to Cerebrovascular Accidents and Subclinical Atherosclerosis in Anti-CCP Negative Spanish Rheumatoid Arthritis Patients. PLoS ONE, 2013, 8, e77695.	1.1	12
22	Association of circulating calprotectin with lipid profile in axial spondyloarthritis. Scientific Reports, 2018, 8, 13728.	1.6	12
23	Influence of MUC5B gene on antisynthetase syndrome. Scientific Reports, 2020, 10, 1415.	1.6	12
24	Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-Î± antagonist therapy. Clinical and Experimental Rheumatology, 2014, 32, 640-6.	0.4	12
25	Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-SchÃ¶nlein purpura (IgA vasculitis). Arthritis Research and Therapy, 2015, 17, 286.	1.6	11
26	Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderateâ€toâ€severe psoriasis undergoing antiâ€tumor necrosis factorâ€Î± therapy. Journal of Dermatology, 2016, 43, 389-394.	0.6	11
27	Significant sE-Selectin levels reduction after 6 months of anti-TNF-Î± therapy in non-diabetic patients with moderate-to-severe psoriasis. Journal of Dermatological Treatment, 2017, 28, 726-730.	1.1	11
28	Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2020, 47, 1344-1353.	1.0	11
29	Antitumour necrosis factor-Î± therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients. Annals of the Rheumatic Diseases, 2013, 72, 1265-1267.	0.5	10
30	Endothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patients. Biomedicines, 2021, 9, 847.	1.4	10
31	Osteoprotegerin CGA Haplotype Protection against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis. PLoS ONE, 2014, 9, e106823.	1.1	10
32	Lack of Association betweenJAK3Gene Polymorphisms and Cardiovascular Disease in Spanish Patients with Rheumatoid Arthritis. BioMed Research International, 2015, 2015, 1-11.	0.9	9
33	Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-Î± antagonist therapy. Clinical and Experimental Rheumatology, 2013, 31, 749-55.	0.4	9
34	Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 1013-1019.	0.4	9
35	Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis. Frontiers in Immunology, 0, 13, .	2.2	9
36	Patients with Ankylosing Spondylitis and Low Disease Activity because of Anti-TNF-Alpha Therapy Have Higher TRAIL Levels Than Controls: A Potential Compensatory Effect. Mediators of Inflammation, 2014, 2014, 1-6.	1.4	8

#	Article	IF	Citations
37	HLA association with the susceptibility to anti-synthetase syndrome. Joint Bone Spine, 2021, 88, 105115.	0.8	8
38	Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study. Arthritis Research and Therapy, 2021, 23, 111.	1.6	7
39	Relationship between endothelial dysfunction and osteoprotegerin, vitamin D, and bone mineral density in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 241-9.	0.4	6
40	TNF-related apoptosis-inducing ligand and cardiovascular disease in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 491-7.	0.4	6
41	IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy. BioMed Research International, 2014, 2014, 1-6.	0.9	5
42	Relative Risk Chart Score for the Assessment of the Cardiovascular Risk in Young Patients with Ankylosing Spondylitis. International Journal of Rheumatology, 2018, 2018, 1-6.	0.9	5
43	BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. Scientific Reports, 2021, 11, 11510.	1.6	5
44	Implication of osteoprotegerin and sclerostin in axial spondyloarthritis cardiovascular disease: study of 163 Spanish patients. Clinical and Experimental Rheumatology, 2018, 36, 302-309.	0.4	5
45	Reclassification into very-high cardiovascular risk after carotid ultrasound in patients with axial spondyloarthritis. Clinical and Experimental Rheumatology, 2020, 38, 724-731.	0.4	5
46	Epidemiological and genetic features of anti-3â€hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review. European Journal of Internal Medicine, 2022, 101, 86-92.	1.0	5
47	Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-Î± antagonist therapy. Clinical and Experimental Rheumatology, 2013, 31, 532-7.	0.4	4
48	Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-Î± therapy. Clinical and Experimental Rheumatology, 2013, 31, 913-8.	0.4	4
49	Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease. Biomedicines, 2021, 9, 458.	1.4	3
50	Angiogenic T Cells: Potential Biomarkers for the Early Diagnosis of Interstitial Lung Disease in Autoimmune Diseases?. Biomedicines, 2022, 10, 851.	1.4	3
51	Obesity and response to biological therapy in rheumatoid arthritis: the role of body mass index and adipose tissue cytokines. Clinical and Experimental Rheumatology, 0, , .	0.4	3
52	Detection of high cardiovascular risk patients with ankylosing spondylitis based on the assessment of abdominal aortic calcium as compared to carotid ultrasound. Arthritis Research and Therapy, 2018, 20, 195.	1.6	2
53	Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitors. Clinical and Experimental Rheumatology, 2022, , .	0.4	2
54	O31â€...Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1

#	Article	IF	Citations
55	Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. Scientific Reports, 2021, 11, 16163.	1.6	1
56	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clinical and Experimental Rheumatology, 0, , .	0.4	1
57	Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 182-187.	0.4	0
58	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
59	Obesity and response to biological therapy in rheumatoid arthritis: the role of body mass index and adipose tissue cytokines.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0